Filing Details
ATOSSA THERAPEUTICS, INC. (NASDAQ:ATOS) filed a Form 8-K with the Securities and Exchange Commission on August 07, 2026, disclosing a material event.
8k filedNASDAQ:ATOS
ATOSSA THERAPEUTICS, INC. (ATOS) Reports Material Event to SEC
ATOSSA THERAPEUTICS, INC. (NASDAQ:ATOS) filed a Form 8-K with the Securities and Exchange Commission on August 07, 2026, disclosing a material event.
At publication ·
What changed
ATOSSA THERAPEUTICS, INC. (NASDAQ:ATOS) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Atossa Therapeutics filed a Form 8-K with the SEC on August 7, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing notice.
- The company's stock trades at $2.36 with a market capitalization of $116.9 million as a healthcare company on the NASDAQ under ticker ATOS.
Market Context
ATOSSA THERAPEUTICS, INC.'s stock currently trades at $2.36 with a market capitalization of $116.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ATOSSA THERAPEUTICS, INC.'s stock.
All SEC filings for ATOSSA THERAPEUTICS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ATOS Stock Page
Frequently Asked Questions
Where can I read ATOS's SEC filings?
Browse all filings on our ATOS SEC filings page.
What types of SEC filings does ATOSSA THERAPEUTICS, INC. file?
Public companies like ATOSSA THERAPEUTICS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
